Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study

M. van Gelder; M. H. van Oers; W. G. Alemayehu; M. C. J. Abrahamse-Testroote; J. J. Cornelissen; M. E. Chamuleau; P. Zachee; M. Hoogendoorn; M. Nijland; E. J. Petersen; A. Beeker; G-J Timmers; L. Verdonck; M. Westerman; O. de Weerdt; A. P. Kater

doi:10.1038/bmt.2016.9

Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study

M. van Gelder^*, M. H. van Oers, W. G. Alemayehu, M. C. J. Abrahamse-Testroote, J. J. Cornelissen, M. E. Chamuleau, P. Zachee, M. Hoogendoorn, M. Nijland, E. J. Petersen, A. Beeker, G-J Timmers, L. Verdonck, M. Westerman, O. de Weerdt, A. P. Kater

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Allogeneic stem cell transplantation (alloSCT) remains the only curative option for CLL patients. Whereas active disease at the time of alloSCT predicts poor outcome, no standard remission-induction regimen exists. We prospectively assessed outcome after cisplatin-containing immune-chemotherapy (R-DHAP) followed by alloSCT in 46 patients (median age 58 years) fulfilling modified European Society for Blood and Marrow Transplantation (EBMT) CLL Transplant Consensus criteria being refractory to or relapsed (R/R) = 3 cycles of R-DHAP and sixteen

Original language	English
Pages (from-to)	799-806
Journal	Bone Marrow Transplantation
Volume	51
Issue number	6
DOIs	https://doi.org/10.1038/bmt.2016.9
Publication status	Published - Jun 2016

Access to Document

10.1038/bmt.2016.9

Cite this

van Gelder, M., van Oers, M. H., Alemayehu, W. G., Abrahamse-Testroote, M. C. J., Cornelissen, J. J., Chamuleau, M. E., Zachee, P., Hoogendoorn, M., Nijland, M., Petersen, E. J., Beeker, A., Timmers, G.-J., Verdonck, L., Westerman, M., de Weerdt, O., & Kater, A. P. (2016). Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study. Bone Marrow Transplantation, 51(6), 799-806. https://doi.org/10.1038/bmt.2016.9

@article{ec477134f94149b4afe645a0a7705940,

title = "Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study",

abstract = "Allogeneic stem cell transplantation (alloSCT) remains the only curative option for CLL patients. Whereas active disease at the time of alloSCT predicts poor outcome, no standard remission-induction regimen exists. We prospectively assessed outcome after cisplatin-containing immune-chemotherapy (R-DHAP) followed by alloSCT in 46 patients (median age 58 years) fulfilling modified European Society for Blood and Marrow Transplantation (EBMT) CLL Transplant Consensus criteria being refractory to or relapsed (R/R) = 3 cycles of R-DHAP and sixteen ",

author = "{van Gelder}, M. and {van Oers}, {M. H.} and Alemayehu, {W. G.} and Abrahamse-Testroote, {M. C. J.} and Cornelissen, {J. J.} and Chamuleau, {M. E.} and P. Zachee and M. Hoogendoorn and M. Nijland and Petersen, {E. J.} and A. Beeker and G-J Timmers and L. Verdonck and M. Westerman and {de Weerdt}, O. and Kater, {A. P.}",

year = "2016",

month = jun,

doi = "10.1038/bmt.2016.9",

language = "English",

volume = "51",

pages = "799--806",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "6",

}

van Gelder, M, van Oers, MH, Alemayehu, WG, Abrahamse-Testroote, MCJ, Cornelissen, JJ, Chamuleau, ME, Zachee, P, Hoogendoorn, M, Nijland, M, Petersen, EJ, Beeker, A, Timmers, G-J, Verdonck, L, Westerman, M, de Weerdt, O & Kater, AP 2016, 'Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study', Bone Marrow Transplantation, vol. 51, no. 6, pp. 799-806. https://doi.org/10.1038/bmt.2016.9

Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study. / van Gelder, M.; van Oers, M. H.; Alemayehu, W. G. et al.
In: Bone Marrow Transplantation, Vol. 51, No. 6, 06.2016, p. 799-806.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Efficacy of cisplatin-based immunochemotherapy plus alloSCT in high-risk chronic lymphocytic leukemia: final results of a prospective multicenter phase 2 HOVON study

AU - van Gelder, M.

AU - van Oers, M. H.

AU - Alemayehu, W. G.

AU - Abrahamse-Testroote, M. C. J.

AU - Cornelissen, J. J.

AU - Chamuleau, M. E.

AU - Zachee, P.

AU - Hoogendoorn, M.

AU - Nijland, M.

AU - Petersen, E. J.

AU - Beeker, A.

AU - Timmers, G-J

AU - Verdonck, L.

AU - Westerman, M.

AU - de Weerdt, O.

AU - Kater, A. P.

PY - 2016/6

Y1 - 2016/6

N2 - Allogeneic stem cell transplantation (alloSCT) remains the only curative option for CLL patients. Whereas active disease at the time of alloSCT predicts poor outcome, no standard remission-induction regimen exists. We prospectively assessed outcome after cisplatin-containing immune-chemotherapy (R-DHAP) followed by alloSCT in 46 patients (median age 58 years) fulfilling modified European Society for Blood and Marrow Transplantation (EBMT) CLL Transplant Consensus criteria being refractory to or relapsed (R/R) = 3 cycles of R-DHAP and sixteen

AB - Allogeneic stem cell transplantation (alloSCT) remains the only curative option for CLL patients. Whereas active disease at the time of alloSCT predicts poor outcome, no standard remission-induction regimen exists. We prospectively assessed outcome after cisplatin-containing immune-chemotherapy (R-DHAP) followed by alloSCT in 46 patients (median age 58 years) fulfilling modified European Society for Blood and Marrow Transplantation (EBMT) CLL Transplant Consensus criteria being refractory to or relapsed (R/R) = 3 cycles of R-DHAP and sixteen

U2 - 10.1038/bmt.2016.9

DO - 10.1038/bmt.2016.9

M3 - Article

SN - 0268-3369

VL - 51

SP - 799

EP - 806

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 6

ER -